Transgene
Develops cancer immunotherapies using vaccines and oncolytic viruses.
TNG | PA
Overview
Corporate Details
- ISIN(s):
- FR0005175080
- LEI:
- 969500PDJW8N0FSGGK69
- Country:
- France
- Address:
- 400 BOULEVARD GONTHIER D'ANDERNACH, 67400 ILLKIRCH-GRAFFENSTADEN
- Website:
- https://www.transgene.fr/en/
Description
Transgene is a clinical-stage biotechnology company that designs and develops immunotherapies for the treatment of cancer. The company's strategy is based on two proprietary technology platforms. The myvac® platform is used to create individualized neoantigen therapeutic vaccines, such as its clinical candidate TG4050, which leverages advanced genetic engineering and artificial intelligence. The invir.IO® platform is dedicated to developing innovative, multifunctional oncolytic viruses engineered to directly destroy cancer cells and modulate the tumor microenvironment, thereby enhancing the patient's immune response against the tumor.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2009-09-02 18:15 |
Transgene : résultats du premier semestre 2009
|
French | 48.9 KB | ||
| 2009-09-02 18:10 |
Transgene : Rapport financier semestriel au 30 juin 2009
|
French | 145.2 KB | ||
| 2009-06-15 08:00 |
TRANSGENE : Innate Pharma, Transgene, ImmunID, Inserm and the cancer hospital C…
|
English | 43.6 KB | ||
| 2009-06-15 08:00 |
Transgene: A l'occasion de l'ouverture du Centre d'Infectiologie de Lyonbiopôle…
|
French | 44.7 KB | ||
| 2009-06-09 17:45 |
TRANSGENE: U.S. Food and Drug Administration gives green light to proceed to Ph…
|
English | 30.7 KB | ||
| 2009-06-09 17:45 |
Transgene: L'agence américaine du médicament (Food and Drug Administration) don…
|
French | 28.7 KB | ||
| 2009-04-30 16:19 |
Transgene : communiqué de mise à disposition du document de référence 2008
|
French | 11.8 KB | ||
| 2009-04-23 17:45 |
Transgene : présentation de données supplémentaires de Phase I dans l'hépatite …
|
French | 26.6 KB | ||
| 2009-04-23 17:45 |
Transgene presents additional Phase I data for TG4040 in hepatitis C chronicall…
|
English | 30.1 KB | ||
| 2009-04-20 17:45 |
TRANSGENE : trésorerie de 81,1 ME au 31 mars 2009
|
French | 17.3 KB | ||
| 2009-04-20 17:45 |
Transgene: Cash position of E81.1 million as of March 31, 2009
|
English | 20.4 KB | ||
| 2009-03-10 18:35 |
Transgene reports full year results 2008
|
English | 79.4 KB | ||
| 2009-03-10 18:30 |
Transgene : Résultats annuels 2008 de Transgene
|
French | 85.0 KB | ||
| 2009-02-17 17:45 |
Transgene confirme un allongement de la durée de vie des patients traités avec …
|
French | 29.7 KB | ||
| 2009-02-17 17:45 |
TRANSGENE confirms longer survival for patients treated with TG4010 in its ongo…
|
English | 49.1 KB |
Automate Your Workflow. Get a real-time feed of all Transgene filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Transgene
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Transgene via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-30 | N/A | Other | Other | 30,898,876 | 32,999,999.57 EUR |
| 2023-05-26 | N/A | Other | Buy | 29,325 | N/A |
Peer Companies
